NeoStem, Inc. , a biopharmaceutical company developing novel cell-based personalized medicine therapies, announced today that the latest available information from continued follow-up for its PreSERVE study will be presented at ACC.15, the American College of Cardiology's 64th Annual Scientific Session and Expo, in San Diego, California. On Sunday, March 15, Dr. Arshed A. Quyyumi, Professor of Medicine at Emory University and Lead Principal Investigator of the PreSERVE AMI study will present results based on one-year follow up of patients in the trial.
http://ift.tt/1zPLn0P
http://ift.tt/1zPLn0P
No comments:
Post a Comment